<![CDATA[Background: “Rheumatoid arthritis (RA) is an inflammatory disease leading to joint disruption”. Theinstant study designed to detect serum markers in RA that could discriminate between seropositive (SP) andseronegative (SN) by evaluating levels of IL- 22and IL -17a in patients with rheumatoid arthritis. Methods:In this cross-sectional study, a total of sixty Rheumatoid arthritis (RA ) patients’ age and sex-matched withhealthy controls were involved in the present study. The serum IL- -22 and IL -17a levels were measuredusing an ELISA kit. Results: The mean ±SD age in seropositive and seronegative was (37.22± 11.29 and34.28±20.3 years, respectively), while in control group was (27.14±9.33 years). Furthermore, serum IL- 22and IL -17a level was significantly higher in seropositive and seronegative RA patients compared to healthycontrols (P<0.001). There was no significant variation in serum IL -22 and IL -17a level according to theseropositive and seronegative in RA patients (p>0.05), but there was a positive correlation between themROC test representing a highly sensitive and specific . Conclusion: The present study exhibited higherserum IL- 22 and IL -17a levels in seropositive and seronegative in RA patients compared to healthy controls.Therefore, IL- 22 and IL -17a can be considered as a biomarker for RA disease, with high sensitivity andspecificity but these cytokines couldn’t be used as discriminated between SP and SN in RA patients.]]>
Copyrights © 2020
